TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy

Shuwen Cao,1,2 Chunhao Lin,1,2 Xiuling Li,1,2 Yixia Liang,1,2 Phei Er Saw1,2 1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China; 2RNA Biomedical Institute, Sun Yat-sen M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cao S, Lin C, Li X, Liang Y, Saw PE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	nanoparticles sirna tme-responsive multistage delivery cancer therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ba1ec390df3d4878ac9e23e81328ace6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ba1ec390df3d4878ac9e23e81328ace6
record_format	dspace
spelling	oai:doaj.org-article:ba1ec390df3d4878ac9e23e81328ace62021-12-02T16:39:49ZTME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy1178-2013https://doaj.org/article/ba1ec390df3d4878ac9e23e81328ace62021-08-01T00:00:00Zhttps://www.dovepress.com/tme-responsive-multistage-nanoplatform-for-sirna-delivery-and-effectiv-peer-reviewed-fulltext-article-IJNhttps://doaj.org/toc/1178-2013Shuwen Cao,1,2 Chunhao Lin,1,2 Xiuling Li,1,2 Yixia Liang,1,2 Phei Er Saw1,2 1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China; 2RNA Biomedical Institute, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of ChinaCorrespondence: Phei Er Saw Email caipeie@mail.sysu.edu.cnAbstract: Since the discovery of RNA interference (RNAi), RNAi technology has rapidly developed into an efficient tool for post-transcriptional gene silencing, which has been widely used for clinical or preclinical treatment of various diseases including cancer. Small interfering RNA (siRNA) is the effector molecule of RNAi technology. However, as polyanionic macromolecules, naked siRNAs have a short circulatory half-life (< 15 min) and is rapidly cleared by renal filtration, which greatly hinders their clinical application. Furthermore, the anionic and macromolecular characteristics of naked siRNAs impede their readiness to cross the cell membrane and therefore delivery vehicles are required to facilitate the cellular uptake and cytosolic delivery of naked siRNAs. In the past decade, numerous nanoparticles (NPs) such as liposomes have been employed for in vivo siRNA delivery, which have achieved favorable therapeutic outcomes in clinical disease treatment. In particular, because tumor microenvironment (TME) or tumor cells show several distinguishing biological/endogenous factors (eg, pH, enzymes, redox, and hypoxia) compared to normal tissues or cells, much attention has recently paid to design and construct TME-responsive NPs for multistaged siRNA delivery, which can respond to biological stimuli to achieve efficient in vivo gene silencing and better anticancer effect. In this review, we summarize recent advances in TME-responsive siRNA delivery systems, especially multistage delivery NPs, and discuss their design principles, functions, effects, and prospects.Keywords: nanoparticles, siRNA, TME-responsive, multistage delivery, cancer therapyCao SLin CLi XLiang YSaw PEDove Medical Pressarticlenanoparticlessirnatme-responsivemultistage deliverycancer therapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 5909-5921 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nanoparticles sirna tme-responsive multistage delivery cancer therapy Medicine (General) R5-920
spellingShingle	nanoparticles sirna tme-responsive multistage delivery cancer therapy Medicine (General) R5-920 Cao S Lin C Li X Liang Y Saw PE TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy
description	Shuwen Cao,1,2 Chunhao Lin,1,2 Xiuling Li,1,2 Yixia Liang,1,2 Phei Er Saw1,2 1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China; 2RNA Biomedical Institute, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of ChinaCorrespondence: Phei Er Saw Email caipeie@mail.sysu.edu.cnAbstract: Since the discovery of RNA interference (RNAi), RNAi technology has rapidly developed into an efficient tool for post-transcriptional gene silencing, which has been widely used for clinical or preclinical treatment of various diseases including cancer. Small interfering RNA (siRNA) is the effector molecule of RNAi technology. However, as polyanionic macromolecules, naked siRNAs have a short circulatory half-life (< 15 min) and is rapidly cleared by renal filtration, which greatly hinders their clinical application. Furthermore, the anionic and macromolecular characteristics of naked siRNAs impede their readiness to cross the cell membrane and therefore delivery vehicles are required to facilitate the cellular uptake and cytosolic delivery of naked siRNAs. In the past decade, numerous nanoparticles (NPs) such as liposomes have been employed for in vivo siRNA delivery, which have achieved favorable therapeutic outcomes in clinical disease treatment. In particular, because tumor microenvironment (TME) or tumor cells show several distinguishing biological/endogenous factors (eg, pH, enzymes, redox, and hypoxia) compared to normal tissues or cells, much attention has recently paid to design and construct TME-responsive NPs for multistaged siRNA delivery, which can respond to biological stimuli to achieve efficient in vivo gene silencing and better anticancer effect. In this review, we summarize recent advances in TME-responsive siRNA delivery systems, especially multistage delivery NPs, and discuss their design principles, functions, effects, and prospects.Keywords: nanoparticles, siRNA, TME-responsive, multistage delivery, cancer therapy
format	article
author	Cao S Lin C Li X Liang Y Saw PE
author_facet	Cao S Lin C Li X Liang Y Saw PE
author_sort	Cao S
title	TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy
title_short	TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy
title_full	TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy
title_fullStr	TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy
title_full_unstemmed	TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy
title_sort	tme-responsive multistage nanoplatform for sirna delivery and effective cancer therapy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/ba1ec390df3d4878ac9e23e81328ace6
work_keys_str_mv	AT caos tmeresponsivemultistagenanoplatformforsirnadeliveryandeffectivecancertherapy AT linc tmeresponsivemultistagenanoplatformforsirnadeliveryandeffectivecancertherapy AT lix tmeresponsivemultistagenanoplatformforsirnadeliveryandeffectivecancertherapy AT liangy tmeresponsivemultistagenanoplatformforsirnadeliveryandeffectivecancertherapy AT sawpe tmeresponsivemultistagenanoplatformforsirnadeliveryandeffectivecancertherapy
_version_	1718383597908393984

TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy

Ejemplares similares